MBMonika L. Burness

Monika L. Burness

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Monika L. Burness has a total of 65 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Targeting bromodomain and extra-terminal proteins reprograms macrophages and inhibits breast cancer progression

    by Deeksha Sharma, Cody G. Hager, Grace G. Bushnell, Alexander P. Kalman, Grace F. Shapiro, Katherine A. Xendzova, Lynne Walenjus, Chloe M. Hutchens, Max S. Wicha, Monika L. Burness

    Introduction: Breast cancer (BC) remains a leading cause of cancer-related deaths, with resistance to therapy driving tumor progression. While immune checkpoint inhibitor (ICI) therapy is effective in some breast cancers, the heterogeneity of treatment responses is partly driven by cancer stem cells (CSCs) and an immunosuppressive tumor microenvironment (TME). Bromodomain and extra-terminal (BET) proteins regulate tumor and immune biology, but their role in innate anti-tumor immunity remains poorly understood. We investigated the role of BET proteins in modulating innate immunity using the potent BET degrader (BETd) ZBC260. Methods: ZBC260 efficacy was evaluated in immunocompetent BALB/c mice bearing D2A1 tumors. NK cells or macrophages were depleted to determine their contribution to BETd response. In vitro , primary murine NK cells, bone marrow-derived macrophages, and THP-1, NK-92 MI, SUM-149, and D2A1 cells were used for co-culture, transwell migration, phagocytosis, qPCR, ELISA, and flow cytometry assays. Single-cell RNA sequencing (scRNA-seq) was performed using 10x Genomics 3′ sequencing and analyzed with Seurat. Results and discussion: ZBC260 inhibited tumor growth in SCID mice but not in NOD-SCID mice, with impaired macrophages and partially compromised NK cells, implicating the innate immune system. To assess the contribution of innate immune cells to BETd efficacy, we depleted NK cells or macrophages in immunocompetent BALB/c mice with D2A1 tumors and treated with ZBC260 or vehicle. Immune depletion studies revealed macrophage loss partially attenuated anti-tumor and anti-CSC effects, highlighting their critical role. To understand the impact of BETd on TME populations, we performed single-cell RNA sequencing, which identified myeloid cells as the predominant population. BETd reduced MRC1⁺immunoregulatory tumor-associated macrophages and enriched CD74+ antigen-presenting macrophages, with upregulated phagosome pathways and enhanced Stat1 activation. In vitro , BETd downregulated M2-associated markers, promoted macrophage phagocytosis, induced tumor cell apoptosis, and inhibited macrophage-driven CSC formation. Collectively, these findings demonstrate that BETd ZBC260 reshapes the TME and reprograms macrophages toward an anti-tumor phenotype, highlighting its translational potential for breast cancer therapy. Conclusion: Collectively, these findings demonstrate that BETd ZBC260 reshapes the TME and reprograms macrophages toward an anti-tumor phenotype, highlighting its translational potential for breast cancer therapy.

  • Open Access

    BET Protein Degrader ZBC260 Induces Tumor Vascular Reprogramming Through Endothelial Cell Remodeling

    by Deeksha Sharma, Cody G Hager, Max S Wicha, Monika L Burness

    Purpose: Endothelial cells regulate angiogenesis, matrix remodeling, and immune responses within the tumor microenvironment, yet endothelial cell heterogeneity across breast cancer subtypes and its regulation by bromodomain and extraterminal domain proteins remain unclear. This study profiled endothelial cells at single-cell resolution in two immunocompetent murine breast cancer models with distinct tumor immune microenvironments: PyMT_FVB/N and D2A1_BALB/c tumors. Methods: Mice were treated intravenously with the bromodomain and extraterminal domain degrader (ZBC260) at 10mg/kg 3 days/week until tumors reached humane endpoints and were harvested. Single-cell RNA sequencing was performed on vehicle and ZBC260 treated tumors (n=3 per condition), and endothelial cell populations were identified and analyzed using Seurat package in R. Results: Six transcriptionally distinct endothelial subpopulations were identified across both breast cancer models, with D2A1 tumors dominated by tip-like and proliferative endothelial cells with strong angiogenic and collagen-producing signatures. ZBC260 reprogrammed endothelial landscape by reducing proliferative, tip-like, and arterial endothelial cells while enriching venous and lymphatic endothelial cells. ZBC260 suppressed hypoxia, glycolysis, and mTORC1 signaling, downregulated angiogenesis and matrix associated pathways and was accompanied by reduced collagen signatures and increased leukocyte adhesion. Cell–cell communication analysis demonstrated that ZBC260 disrupted endothelial cells interactions with tumor and immune cells, by disrupting ligand–receptor communications and attenuating NOTCH, TGF-β, and VEGF signaling networks that sustain angiogenesis and immune suppression. Conclusion: Together, these findings highlight endothelial diversity across breast cancer models and identify ZBC260 as a regulator of tumor endothelial states. ZBC260 reprograms endothelial heterogeneity and remodels the tumor vascular landscape. The transcriptomic and cell–cell communication changes observed are consistent with the establishment of a more immune-permissive tumor microenvironment, supporting the potential of BET degradation as a strategy to complement immunotherapy and improve therapeutic responsiveness in breast cancer.

  • Open Access

    Supplementary Data from Natural Killer Cell Regulation of Breast Cancer Stem Cells Mediates Metastatic Dormancy

    by Grace G. Bushnell, Deeksha Sharma, Henry C. Wilmot, Michelle Zheng, Toluwaleke D. Fashina, Chloe M. Hutchens, Samuel Osipov, Monika Burness, Max S. Wicha

    Supplemental figures and captions

  • Open Access

    Bromodomain and extra-terminal proteins in solid tumors: regulators of immune microenvironment and emerging therapeutic targets

    by Deeksha Sharma, Grace G. Bushnell, Alexander P. Kalman, Chloe M. Hutchens, Monika L. Burness

    Bromodomain and Extra-Terminal domain (BET) proteins are key epigenetic readers that recognize and bind acetylated lysine residues on histones, orchestrating transcriptional programs that drive oncogenic processes. BET proteins regulate the expression of oncogenes involved in proliferation, survival, and differentiation, thereby promoting tumor initiation, progression, and therapy resistance across a wide range of solid tumors. Recent findings implicate BET proteins in maintaining cancer stem cells (CSCs), a subpopulation of tumor cells characterized with self-renewal capacity, plasticity, and the ability to evade conventional therapies. In CSCs, BET proteins coordinate stemness-associated transcriptional networks, and drive tumor persistence, metastasis, and relapse following treatment. BET proteins also shape the tumor immune microenvironment by modulating the expression of key immune checkpoint molecules such as PD-L1, regulating cytokine production, and controlling antigen presentation, which collectively influence adaptive and innate immune responses. BET inhibition enhances T cell infiltration and activation while suppressing the immunosuppressive functions of tumor-associated macrophages. The dual role of BET proteins in controlling both stemness and immune regulation positions them as central regulators of tumor-intrinsic and immune-mediated mechanisms in cancer. This makes BET proteins attractive therapeutic targets, as their inhibition offers the potential to simultaneously suppress tumor growth and reprogram the immune microenvironment. Preclinical and early clinical studies demonstrate that combining BET inhibitors with chemotherapy, targeted therapies, or immune checkpoint blockade synergizes anti-tumor responses. Future research focused on understanding the context-specific functions of BET proteins, and optimizing combination strategies will be critical to fully harness their therapeutic potential in solid tumors.


  • Open Access

    Supplementary Data from Natural Killer Cell Regulation of Breast Cancer Stem Cells Mediates Metastatic Dormancy

    by Grace G. Bushnell, Deeksha Sharma, Henry C. Wilmot, Michelle Zheng, Toluwaleke D. Fashina, Chloe M. Hutchens, Samuel Osipov, Monika Burness, Max S. Wicha

    Supplemental figures and captions

  • Open Access

    Data from Natural Killer Cell Regulation of Breast Cancer Stem Cells Mediates Metastatic Dormancy

    by Grace G. Bushnell, Deeksha Sharma, Henry C. Wilmot, Michelle Zheng, Toluwaleke D. Fashina, Chloe M. Hutchens, Samuel Osipov, Monika Burness, Max S. Wicha

    Patients with breast cancer with estrogen receptor–positive tumors face a constant risk of disease recurrence for the remainder of their lives. Dormant tumor cells residing in tissues such as the bone marrow may generate clinically significant metastases many years after initial diagnosis. Previous studies suggest that dormant cancer cells display “stem-like” properties (cancer stem cell, CSC), which may be regulated by the immune system. To elucidate the role of the immune system in controlling dormancy and its escape, we studied dormancy in immunocompetent, syngeneic mouse breast cancer models. Three mouse breast cancer cell lines, PyMT, Met1, and D2.0R, contained CSCs that displayed short- and long-term metastatic dormancy in vivo, which was dependent on the host immune system. Each model was regulated by different components of the immune system. Natural killer (NK) cells were key for the metastatic dormancy phenotype in D2.0R cells. Quiescent D2.0R CSCs were resistant to NK cell cytotoxicity, whereas proliferative CSCs were sensitive. Resistance to NK cell cytotoxicity was mediated, in part, by the expression of BACH1 and SOX2 transcription factors. Expression of STING and STING targets was decreased in quiescent CSCs, and the STING agonist MSA-2 enhanced NK cell killing. Collectively, these findings demonstrate the role of immune regulation of breast tumor dormancy and highlight the importance of utilizing immunocompetent models to study this phenomenon.Significance: The immune system controls disseminated breast cancer cells during disease latency, highlighting the need to utilize immunocompetent models to identify strategies for targeting dormant cancer cells and reducing metastatic recurrence.See related commentary by Cackowski and Korkaya, p. 3319


  • Open Access

    Natural Killer Cell Regulation of Breast Cancer Stem Cells Mediates Metastatic Dormancy

    by Grace G. Bushnell, Deeksha Sharma, Henry C. Wilmot, Michelle Zheng, Toluwaleke D. Fashina, Chloe M. Hutchens, Samuel Osipov, Monika Burness, Max S. Wicha

    Patients with breast cancer with estrogen receptor–positive tumors face a constant risk of disease recurrence for the remainder of their lives. Dormant tumor cells residing in tissues such as the bone marrow may generate clinically significant metastases many years after initial diagnosis. Previous studies suggest that dormant cancer cells display “stem-like” properties (cancer stem cell, CSC), which may be regulated by the immune system. To elucidate the role of the immune system in controlling dormancy and its escape, we studied dormancy in immunocompetent, syngeneic mouse breast cancer models. Three mouse breast cancer cell lines, PyMT, Met1, and D2.0R, contained CSCs that displayed short- and long-term metastatic dormancy in vivo, which was dependent on the host immune system. Each model was regulated by different components of the immune system. Natural killer (NK) cells were key for the metastatic dormancy phenotype in D2.0R cells. Quiescent D2.0R CSCs were resistant to NK cell cytotoxicity, whereas proliferative CSCs were sensitive. Resistance to NK cell cytotoxicity was mediated, in part, by the expression of BACH1 and SOX2 transcription factors. Expression of STING and STING targets was decreased in quiescent CSCs, and the STING agonist MSA-2 enhanced NK cell killing. Collectively, these findings demonstrate the role of immune regulation of breast tumor dormancy and highlight the importance of utilizing immunocompetent models to study this phenomenon. Significance: The immune system controls disseminated breast cancer cells during disease latency, highlighting the need to utilize immunocompetent models to identify strategies for targeting dormant cancer cells and reducing metastatic recurrence. See related commentary by Cackowski and Korkaya, p. 3319


  • Open Access

    The BET degrader ZBC260 suppresses stemness and tumorigenesis and promotes differentiation in triple-negative breast cancer by disrupting inflammatory signaling

    by Deeksha Sharma, Cody G. Hager, Li Shang, Lam Tran, Yongyou Zhu, Aihui Ma, Brian Magnuson, Matthew W. Lesko, Max S. Wicha, Monika L. Burness

    Background: Breast cancer stem cells (BCSCs) are resistant to standard therapies, facilitate tumor dissemination, and contribute to relapse and progression. Super-enhancers are regulators of stemness, and BET proteins, which are critical for super-enhancer function, are a potential therapeutic target. Here, we investigated the effects of BET proteins on the regulation of breast cancer stemness using the pan-BET degrader ZBC260.Methods: We evaluated the effect of ZBC260 on CSCs in TNBC cell lines. We assessed the effect of ZBC260 on cellular viability and tumor growth and measured its effects on cancer stemness. We used RNA sequencing and stemness index to determine the global transcriptomic changes in CSCs and bulk cells and further validated our findings by qPCR, western blot, and ELISA.Results: ZBC260 potently inhibited TNBC growth both in vitro and in vivo. ZBC260 reduced stemness as measured by cell surface marker expression, ALDH activity, tumorsphere number, and stemness index while increasing differentiated cells. GSEA analysis indicated preferential downregulation of stemness-associated and inflammatory genes by ZBC260 in ALDH+CSCs.Conclusions: The BET degrader ZBC260 is an efficient degrader of BET proteins that suppresses tumor progression and decreases CSCs through the downregulation of inflammatory genes and pathways. Our findings support the further development of BET degraders alone and in combination with other therapeutics as CSC targeting agents.


  • Factors influencing scalp cooling discussions and use at a large academic institution: a single-center retrospective review

    by Taylor Novice, Madison Novice, David Portney, Joshua Goyert, N. Lynn Henry, Jacqueline S. Jeruss, Monika L. Burness

    Purpose Chemotherapy-induced alopecia (CIA) is a stigmatizing and psychologically devasting side effect of cancer treatment. Scalp cooling therapy (SCT) is the most effective method to reduce CIA, yet it is underutilized. We investigated factors that may impact scalp cooling discussion and use. Methods We performed a retrospective review of cancer patients from 2000 to 2019 who had documentation of SCT discussion in the electronic medical record. The University of Michigan Rogel Cancer Center registry was used to identify the total number of cancer patients eligible for SCT during 2015–2019. Chi-square tests were used for outcome and patient characteristic comparisons (p < 0.05). Results From 2000 to 2019, 194 patients had documentation of SCT discussion. Of those, 72 (43.6%) used SCT, 93 (47.9%) did not use SCT, and the remaining 29 (17.8%) had unknown SCT use. A total of 5615 cancer patients were eligible for SCT from 2015 to 2019. As compared to those who did not have documented SCT discussions, patients who had documentation of SCT discussions in that period (n = 161, 3.0%) were more likely to be female, have breast cancer, be less than 45 years old, and live in a zip code with average income > US $100,000 (all p < 0.0001). Between 2015 and 2019, 57 patients (1.02%) used SCT. On univariate analysis, patient-initiated conversation about SCT (p = 0.01) and age less than 65 (p = 0.03) were significantly associated with decision to use SCT. Conclusion There were distinctions in the types of patients who have documented discussions about SCT. Improving patient knowledge about the availability of SCT and increasing access to this technology for all eligible cancer patients may enable more patients to achieve improved quality of life by reducing or preventing CIA.


  • Identifying Barriers and Facilitators to Scalp Cooling Therapy Through a National Survey of the Awareness, Practice Patterns, and Attitudes of Oncologists

    by Madison Novice, Taylor Novice, N. Lynn Henry, Kyle Johnson, Jacqueline S. Jeruss, Kelley M. Kidwell, Monika L. Burness

    PURPOSE: Scalp cooling therapy (SCT) is the most effective method to reduce chemotherapy-induced alopecia (CIA), a highly distressing side effect of cancer treatment. Despite data supporting SCT efficacy and safety, SCT use in the United States is not widespread. Oncologists' interactions with scalp cooling were examined to identify facilitators and barriers to SCT implementation. METHODS: A 33-question survey was distributed through the ASCO Research Survey Pool to a nationally representative, random sample of 600 oncology providers. Outcome measures included knowledge of SCT, frequency of initiating conversations about SCT with patients, degree of support, and barriers for SCT. Significance was defined as P < .001. RESULTS: Of 155 (25.8%) responding providers, 62% of providers were in favor of SCT always or most of the time, but only 26% reported initiating discussions about SCT always or most of the time. Providers who treat breast cancer ( P ≤ .0001), those who report being very familiar with SCT ( P ≤ .0001), those who report having read SCT literature in the past 2 years ( P ≤ .0001), and those who work at a facility with machine SCT ( P ≤ .0001) were significantly more likely to initiate conversations with patients about SCT. Financial concerns (58%) were the primary reason for not recommending SCT use; efficacy (31%), staff or facility (24%), and safety (15%) concerns were also noted. Although safety concerns have decreased markedly over time, 14% of providers report patients who continue to express these concerns and 17% of providers see safety issues as barriers to supporting SCT. CONCLUSION: Our findings suggest that oncology provider familiarity and experience with SCT lead to increased support for scalp cooling, which may ultimately result in greater availability and utilization of SCT when indicated.